Splash Beverage acquires exclusive global rights to CannEpil epilepsy therapy from Argent BioPharma

SPLASH BEVERAGE GROUP, INC.

Exclusive global license for CannEpil, a cannabinoid-based therapy for drug-resistant epilepsy already used in Europe.
Consideration includes $1M investment from C/M Capital, $5M debt forgiveness, and $5.5M preferred equity issuance.
Argent BioPharma to receive 15% royalty on net revenue from worldwide sales of CannEpil.
CannEpil has FDA pre-IND engagement and an IND number for U.S. clinical development.
Drug-resistant epilepsy affects ~30% of epilepsy patients; therapy has EU-GMP manufacturing and European patient access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.